Cardiac resynchronization therapy (CRT), with or without a defibrillator, has been shown to improve symptoms, quality of life, and prognosis in patients with moderate-to-severe heart failure (HF) ...

Reduced cardiac efficiency caused by suboptimal synchronization of the heart's normal contraction might contribute to the development of or exacerbate heart failure. Conceptually and in practice ...

LOS ANGELES (March 8, 2002) – Patients who suffer from advanced congestive heart failure and heart rhythm abnormalities may qualify to participate in one of two research trials now underway at ...

Results from the multi-center CRT-NEXT study demonstrated that CRT-DX is as safe and effective as conventional three-lead CRT ...

The results of the MADIT-CRT trial, reported at the ESC 2009, add yet another randomized trial to the evidence base supporting cardiac resynchronization therapy. The trial, which randomized NYHA class ...

Please provide your email address to receive an email when new articles are posted on . Long-term CRT-D use was tied to improved survival and time to adverse events vs. ICD therapy in patients with ...

Shanghai, China - The first patient implants of the Boston Scientific Corporation COGNIS™ cardiac resynchronization therapy defibrillator (CRT-D) were successfully performed in China’s Zhejiang ...

Medtronic CRT-D Devices Demonstrate Survival Benefits for Mildly Symptomatic Heart Failure Patients in Two Pivotal Clinical Trials MINNEAPOLIS – Medtronic, Inc. today announced that the U.S. Food and ...

Medtronic announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.

A Baylor College of Medicine multi-institution, collaborative study to determine the effectiveness and safety of commonly used pacing treatments for cardiac resynchronization therapy in people with ...

6MWD: 6-min walk distance; CARE-HF: Cardiac Resynchronization-Heart Failure; COMPANION: Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure; CRT-D: Cardiac resynchronization ...

DUBLIN, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it has received CE (Conformité Européenne) Mark for its Cobalt™ and Crome™ portfolio of implantable ...